Definitions
Sorry, no definitions found. You may find more data at relapsing-remitting.
Etymologies
Sorry, no etymologies found.
Support
Help support Wordnik (and make this page ad-free) by adopting the word Relapsing-Remitting.
Examples
-
I was dianosed with Relapsing-Remitting Multiple Sclerosis in 2001 after a mild (though scary to me) exacerbation.
-
April 14, 2010 from 6: 00 to 7: 30 p.m. at Poster Session P04, located at P04. 211 in the poster hall under the following title: Safety and Efficacy of Autologous T-Cell Immunotherapy (Tovaxin) in Patients with Active Relapsing-Remitting Multiple Sclerosis.
-
The most common is Relapsing-Remitting (RR) MS, which is characterized by flare-ups, followed by periods of improvement.
unknown title 2009
-
About 85\% of MS patients are thought to have Relapsing-Remitting MS.
-
Opexa is preparing for a Phase III clinical trial with Tovaxin in Relapsing-Remitting Multiple Sclerosis (RRMS) following the completion of a Phase IIb clinical study in 150 patients with MS. Data from this clinical study show evidence that RRMS patients treated with Tovaxin saw overall clinical and disability benefits over the placebo group, including a clinically relevant decrease in the Annualized Relapse Rate (ARR), and improvement in disability score (EDSS), as well as an excellent safety profile with no serious adverse events related to Tovaxin treatment.
unknown title 2011
-
Opexa is preparing for a Phase III clinical trial with Tovaxin in Relapsing-Remitting Multiple Sclerosis (RRMS) following the completion of a Phase IIb clinical study in 150 patients with MS. Data from this clinical study show evidence that RRMS patients treated with Tovaxin saw overall clinical and disability benefits over the placebo group, including a clinically relevant decrease in the Annualized Relapse Rate (ARR), and improvement in disability score (EDSS), as well as an excellent safety profile with no serious adverse events related to Tovaxin treatment.
unknown title 2011
-
About the Phase II Trimesta Clinical Trial for Relapsing-Remitting Multiple Sclerosis
unknown title 2011
-
Rebif (R) (interferon beta-1a) Platform presentations - Measures of Early Clinical Activity as Prognostic Factors for Long-Term Clinical Outcomes in Relapsing-Remitting Multiple Sclerosis (presentation S01. 005, Tuesday, April 13, 2010, 2: 45 pm EDT) - Subcutaneous Interferon beta-1a Treatment and Pregnancy Outcomes in Patients with Multiple Sclerosis
-
Rebif (R) (interferon beta-1a) Platform presentations - Measures of Early Clinical Activity as Prognostic Factors for Long-Term Clinical Outcomes in Relapsing-Remitting Multiple Sclerosis (presentation S01. 005, Tuesday, April 13, 2010, 2: 45 pm EDT) - Subcutaneous Interferon beta-1a Treatment and Pregnancy Outcomes in Patients with Multiple Sclerosis
-
Rebif (R) (interferon beta-1a) Platform presentations - Measures of Early Clinical Activity as Prognostic Factors for Long-Term Clinical Outcomes in Relapsing-Remitting Multiple Sclerosis (presentation S01. 005, Tuesday, April 13, 2010, 2: 45 pm EDT) - Subcutaneous Interferon beta-1a Treatment and Pregnancy Outcomes in Patients with Multiple Sclerosis
Comments
Log in or sign up to get involved in the conversation. It's quick and easy.